See more : UCapital24 S.p.A. (U24.MI) Income Statement Analysis – Financial Results
Complete financial analysis of TerrAscend Corp. (TRSSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TerrAscend Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- ISS A/S (ISSDY) Income Statement Analysis – Financial Results
- Culpeo Minerals Limited (CPO.AX) Income Statement Analysis – Financial Results
- Capital Group Holdings, Inc. (CGHC) Income Statement Analysis – Financial Results
- Jiangsu Zijin Rural Commercial Bank Co.,Ltd (601860.SS) Income Statement Analysis – Financial Results
- Reliance Infrastructure Limited (RELINFRA.BO) Income Statement Analysis – Financial Results
TerrAscend Corp. (TRSSF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.terrascend.com
About TerrAscend Corp.
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. It produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis infused artisan edibles. The company also operates three retail dispensaries under the Apothecarium brand name in California and Pennsylvania. In addition, it owns various synergistic under Gage Cannabis, Ilera Healthcare, Kind Tree, Prism, State Flower, Valhalla Confections, and Arise Bioscience Inc. brands. As of July 26, 2022, the company operated 27 dispensaries, including 3 Cookies dispensaries in Michigan and 1 in Toronto. TerrAscend Corp. was incorporated in 2017 and is headquartered in Mississauga, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 317.33M | 322.64M | 243.49M | 198.32M | 84.87M | 6.83M | 0.00 | 0.00 |
| Cost of Revenue | 157.63M | 203.07M | 109.38M | 171.98M | 87.52M | 10.17M | 381.32K | 0.00 |
| Gross Profit | 159.70M | 119.57M | 134.11M | 26.34M | -2.65M | -3.34M | -381.32K | 0.00 |
| Gross Profit Ratio | 50.33% | 37.06% | 55.08% | 13.28% | -3.12% | -48.96% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 426.00K | 709.00K | 141.00K | 0.00 | 0.00 |
| General & Administrative | 100.35M | 101.22M | 71.85M | 57.01M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 9.66M | 10.32M | 1.86M | 1.67M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 110.01M | 150.48M | 94.16M | 75.17M | 61.68M | 24.67M | 6.27M | 866.94K |
| Other Expenses | 72.69M | 206.00K | 230.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 182.69M | 150.48M | 94.16M | 75.60M | 62.39M | 24.81M | 6.27M | 866.94K |
| Cost & Expenses | 340.32M | 353.55M | 203.54M | 247.58M | 149.91M | 34.98M | 6.66M | 866.94K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 640.18K | 36.28K | 9.00 |
| Interest Expense | 35.11M | 39.06M | 24.99M | 7.03M | 4.09M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 22.70M | 32.03M | 17.38M | 16.57M | 7.32M | 921.00K | 244.08K | 0.00 |
| EBITDA | -1.03M | -320.94M | 104.54M | -96.45M | -204.22M | -20.52M | -6.56M | -866.94K |
| EBITDA Ratio | -0.32% | 0.35% | 23.54% | -16.48% | -68.01% | -398.97% | 0.00% | 0.00% |
| Operating Income | -23.00M | -30.91M | 39.95M | -49.26M | -65.04M | -28.16M | -6.66M | -866.94K |
| Operating Income Ratio | -7.25% | -9.58% | 16.41% | -24.84% | -76.63% | -412.47% | 0.00% | 0.00% |
| Total Other Income/Expenses | -35.84M | -279.28M | 15.88M | -77.21M | -152.29M | 6.72M | -149.23K | -244.00 |
| Income Before Tax | -58.83M | -403.82M | 55.83M | -126.47M | -217.33M | -21.44M | -6.81M | -867.18K |
| Income Before Tax Ratio | -18.54% | -125.16% | 22.93% | -63.77% | -256.08% | -314.09% | 0.00% | 0.00% |
| Income Tax Expense | 23.45M | -14.04M | 36.20M | 27.87M | 1.62M | 704.00K | -3.00 | 0.00 |
| Net Income | -91.10M | -429.49M | 3.90M | -155.12M | -215.79M | -22.03M | -6.81M | -867.18K |
| Net Income Ratio | -28.71% | -133.12% | 1.60% | -78.22% | -254.26% | -322.71% | 0.00% | 0.00% |
| EPS | -0.33 | -1.76 | 0.02 | -1.04 | -2.17 | -0.24 | -0.18 | -0.03 |
| EPS Diluted | -0.33 | -1.76 | 0.02 | -1.04 | -2.17 | -0.24 | -0.18 | -0.03 |
| Weighted Avg Shares Out | 279.29M | 244.35M | 181.06M | 149.74M | 99.59M | 90.98M | 37.63M | 29.24M |
| Weighted Avg Shares Out (Dil) | 279.29M | 244.35M | 208.71M | 149.74M | 99.59M | 90.98M | 37.63M | 29.24M |
Will These Marijuana Stocks See A Recovery Before Next Month?
Best Marijuana Stocks To Watch Next Week As New Jersey Begins Recreational Cannabis Sales
Best Marijuana Stocks To Buy Now? 3 Cannabis Stocks For Your List In April
New Jersey Approves Adult-Use Cannabis Sales To Launch Within Weeks
Cannabis Stocks: Near-Term Headwinds Don't Matter Much (Podcast Transcript)
Cannabis Stocks: Near-Term Headwinds Don't Matter Much
What Marijuana Stocks Should You Buy Today? 3 Options To Consider
3 Marijuana Stocks To Watch Before The House Votes On Federal Reform
Cannabis Industry Growth Will Return In Second Half Of 2022 (Podcast Transcript)
3 Top Marijuana Stocks For Your Watchlist Right Now
Source: https://incomestatements.info
Category: Stock Reports